The combined serological test based on the IgA antibody against the EBV capsid antigen (VCA-IgA) and the IgA antibody against EBV nuclear antigen 1 (EBNA1-IgA) by enzyme-linked immunosorbent assay (ELISA) was used for NPC screening in endemic areas in China (Gao et al., 2017; Liu et al., 2012; Yu et al., 2018). This evidence concerns the gene CD79A and nasopharyngeal carcinoma.